Further bad news for Emergent BioSolutions (NYSE: EBS) caused the US company’s share price to drop by 37% on Friday.
The Maryland-based firm disclosed in a filing to the US Securities and Exchange Commission that, by mutual agreement with the US Department of Health and Human Services (HHS), the company's 2012 Center for Innovation in Advanced Development and Manufacturing contract to establish a public-private partnership for pandemic preparedness was to be terminated, along with all associated task orders.
This includes the 2020 task order to reserve capacity and expand manufacturing for third-party COVID-19 vaccine and therapeutic candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze